Antisense oligodeoxynucleotides to latent membrane protein 1 induce growth inhibition, apoptosis and Bcl‐2 suppression in Epstein‐Barr virus (EBV)‐transformed B‐lymphoblastoid cells, but not in EBV‐positive natural killer cell lymphoma cells
暂无分享,去创建一个
T. Yoshino | M. Takata | J. Tsuchiyama | K. Shinagawa | M. Harada | K. Ikeda | M. Harada | Kazuhiko Yamamoto | K. Yamamoto | A. Ashiba | T. Noguchi | I. Yoshida | Toshio Noguchi | Atsuko Ashiba | Isao Yoshida | Junjiro Tsuchiyama
[1] C. Meijer,et al. No direct role for Epstein‐Barr virus in oral carcinogenesis: A study at the DNA, RNA and protein levels , 2000, International journal of cancer.
[2] K. Ohshima,et al. Nasal lymphomas in Japan: a high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene. , 1999, Leukemia & lymphoma.
[3] S. Dirnhofer,et al. High prevalence of a 30-base pair deletion in the Epstein-Barr virus (EBV) latent membrane protein 1 gene and of strain type B EBV in Mexican classical Hodgkin's disease and reactive lymphoid tissue. , 1999, Human pathology.
[4] M. Ueffing,et al. Latent membrane protein 1 of Epstein–Barr virus interacts with JAK3 and activates STAT proteins , 1999, The EMBO journal.
[5] L. Young,et al. Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Activates the JNK Pathway through Its Extreme C Terminus via a Mechanism Involving TRADD and TRAF2 , 1999, Journal of Virology.
[6] J. Lacy,et al. Antisense to the epstein-barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. , 1998, Blood.
[7] T. Yoshino,et al. Characterization of a Novel Human Natural Killer-Cell Line (NK-YS) Established From Natural Killer Cell Lymphoma/Leukemia Associated With Epstein-Barr Virus Infection , 1998 .
[8] W. Hammerschmidt,et al. Epstein–Barr virus‐mediated B‐cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor , 1998, The EMBO journal.
[9] A. Eliopoulos,et al. Epstein–Barr virus: LMP1 masquerades as an active receptor , 1998, Current Biology.
[10] T. Yoshino,et al. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. , 1998, Blood.
[11] W. Kolch,et al. Epstein–Barr virus latent membrane protein‐1 triggers AP‐1 activity via the c‐Jun N‐terminal kinase cascade , 1997, The EMBO journal.
[12] P. Quesenberry,et al. The 30-bp deletion variant of Epstein-Barr virus-encoded latent membrane protein-1 prevails in acute infectious mononucleosis. , 1997, The Journal of infectious diseases.
[13] M. Ueffing,et al. Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule , 1997, The EMBO journal.
[14] D. Baltimore,et al. Localization of the Major NF-κB-activating Site and the Sole TRAF3 Binding Site of LMP-1 Defines Two Distinct Signaling Motifs* , 1997, The Journal of Biological Chemistry.
[15] M. Sandberg,et al. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3 , 1997, Journal of virology.
[16] E. Jaffe,et al. Prevalence of Epstein-Barr viral sequences and EBV LMP1 oncogene deletions in Burkitt's lymphoma from Pakistan: epidemiological correlations. , 1997, Human pathology.
[17] A. Carbone,et al. Epstein-Barr virus strains with latent membrane protein-1 deletions: prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease. , 1997, Blood.
[18] E. Kieff,et al. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation , 1997, Journal of virology.
[19] E. Kieff,et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation , 1996, Molecular and cellular biology.
[20] G. Srivastava,et al. Nasal NK‐ and T‐cell lymphomas share the same type of Epstein‐Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease , 1996, International journal of cancer.
[21] E. Kieff,et al. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[22] E. Jaffe,et al. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas , 1996 .
[23] P. Murray,et al. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. , 1996, Blood.
[24] E. Kieff. Epstein-Barr virus and its replication , 1996 .
[25] S. Jiang,et al. Bcl-2 is expressed in human natural killer cells and is regulated by interleukin-2. , 1996, Natural immunity.
[26] E. Jaffe,et al. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas. , 1996, Blood.
[27] Yi-Song Wang,et al. The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. , 1995, Oncogene.
[28] F. Ho,et al. Treatment outcome and prognostic factors for primary nasal lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] C. Ware,et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family , 1995, Cell.
[30] E. Kieff,et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. , 1995, Immunity.
[31] M. Rowe,et al. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers , 1994, Journal of virology.
[32] D. Liebowitz. Nasopharyngeal carcinoma: the Epstein-Barr virus association. , 1994, Seminars in oncology.
[33] E. Kieff,et al. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[34] Martine,et al. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. , 1993, The American journal of pathology.
[35] E. Kieff,et al. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation , 1993, Journal of virology.
[36] M. Fukuda,et al. Detection of Epstein-Barr virus genome in natural-killer-like cell line, YT. , 1992, Leukemia.
[37] E. Kieff,et al. Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death , 1991, Cell.
[38] U. Nater,et al. Epstein-Barr virus. , 1991, The Journal of family practice.
[39] E. Kieff,et al. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation , 1991, Journal of virology.
[40] J. Martin,et al. Immortalizing genes of Epstein-Barr virus. , 1991, Advances in virus research.
[41] E. Kieff,et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23 , 1990, Journal of virology.
[42] W. Hammerschmidt,et al. Genetic analysis of immortalizing functions of EpsteinBarr virus in human B lymphocytes , 1989, Nature.
[43] V. Baichwal,et al. Posttranslational processing of an Epstein-Barr virus-encoded membrane protein expressed in cells transformed by Epstein-Barr virus , 1987, Journal of virology.
[44] E. Kieff,et al. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus , 1986, Journal of virology.
[45] E. Kieff,et al. A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[46] E. Kieff,et al. Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein , 1984, Journal of virology.